- Home
- MTEM vs BCDA Comparison
MTEM vs BCDA Comparison
Compare MTEM & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEM
- BCDA
- Stock Information
- Founded
- MTEM 2001
- BCDA N/A
- Country
- MTEM United States
- BCDA United States
- Employees
- MTEM N/A
- BCDA N/A
- Industry
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- MTEM Health Care
- BCDA Health Care
- Exchange
- MTEM Nasdaq
- BCDA Nasdaq
- Market Cap
- MTEM 9.7M
- BCDA 7.9M
- IPO Year
- MTEM N/A
- BCDA N/A
- Fundamental
- Price
- MTEM $0.71
- BCDA $2.60
- Analyst Decision
- MTEM
- BCDA Strong Buy
- Analyst Count
- MTEM 0
- BCDA 1
- Target Price
- MTEM N/A
- BCDA $25.00
- AVG Volume (30 Days)
- MTEM 13.4M
- BCDA 74.1K
- Earning Date
- MTEM 11-11-2024
- BCDA 11-06-2024
- Dividend Yield
- MTEM N/A
- BCDA N/A
- EPS Growth
- MTEM N/A
- BCDA N/A
- EPS
- MTEM N/A
- BCDA N/A
- Revenue
- MTEM $25,470,000.00
- BCDA $428,000.00
- Revenue This Year
- MTEM N/A
- BCDA $6.92
- Revenue Next Year
- MTEM N/A
- BCDA N/A
- P/E Ratio
- MTEM N/A
- BCDA N/A
- Revenue Growth
- MTEM N/A
- BCDA 0.71
- 52 Week Low
- MTEM $0.30
- BCDA $1.96
- 52 Week High
- MTEM $6.48
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- MTEM 38.68
- BCDA 46.60
- Support Level
- MTEM $0.31
- BCDA $2.39
- Resistance Level
- MTEM $1.34
- BCDA $2.84
- Average True Range (ATR)
- MTEM 0.14
- BCDA 0.17
- MACD
- MTEM -0.05
- BCDA -0.00
- Stochastic Oscillator
- MTEM 34.48
- BCDA 41.18
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).